Switch theme
Sign up to access all valuation multiples
Fangzhou Inc is a online chronic disease management platform in China. It has focus on chronic disease management to address the needs of patients with chronic diseases, such as hypertension, cardiovascular and respiratory chronic diseases. The company provide comprehensive medical services and online retail pharmacy services through Jianke Platform. The principal segment of the group are online retail pharmacy services, comprehensive medical services and customized content and marketing solutions. Key revenue is generated from Online retail pharmacy services.
2019
n/a
LTM Revenue n/a
LTM EBITDA n/a
$549M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Fangzhou has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Fangzhou achieved revenue of $313M and an EBITDA of -$22.5M.
Fangzhou expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Fangzhou valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $283M | $313M | XXX | XXX | XXX |
| Gross Profit | $28.2M | $48.9M | XXX | XXX | XXX |
| Gross Margin | 10% | 16% | XXX | XXX | XXX |
| EBITDA | -$46.9M | -$22.5M | XXX | XXX | XXX |
| EBITDA Margin | -17% | -7% | XXX | XXX | XXX |
| Net Profit | -$39.1M | -$49.3M | XXX | XXX | XXX |
| Net Margin | -14% | -16% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Fangzhou's stock price is HKD 3 (or $0).
Fangzhou has current market cap of HKD 4.5B (or $577M), and EV of HKD 4.3B (or $549M).
See Fangzhou trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $549M | $577M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Fangzhou has market cap of $577M and EV of $549M.
Fangzhou's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Fangzhou's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Fangzhou and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $549M | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | -24.4x | XXX | XXX | XXX |
| P/E | -22.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 256.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpFangzhou's NTM/LTM revenue growth is n/a
Fangzhou's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Fangzhou's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Fangzhou's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Fangzhou and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -7% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -52% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 21% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| Oriola | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fangzhou acquired XXX companies to date.
Last acquisition by Fangzhou was XXXXXXXX, XXXXX XXXXX XXXXXX . Fangzhou acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Fangzhou founded? | Fangzhou was founded in 2019. |
| Where is Fangzhou headquartered? | Fangzhou is headquartered in Hong Kong. |
| Is Fangzhou publicy listed? | Yes, Fangzhou is a public company listed on HKG. |
| What is the stock symbol of Fangzhou? | Fangzhou trades under 06086 ticker. |
| When did Fangzhou go public? | Fangzhou went public in 2024. |
| Who are competitors of Fangzhou? | Similar companies to Fangzhou include e.g. MedPlus India, Pague Menos, Droga Raia, Redcare Pharmacy. |
| What is the current market cap of Fangzhou? | Fangzhou's current market cap is $577M |
| What is the current revenue growth of Fangzhou? | Fangzhou revenue growth between 2023 and 2024 was 10%. |
| Is Fangzhou profitable? | Yes, Fangzhou is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
